• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

REASONS OB IS GETTING HAMMERED!

Quote

Anonymous

Guest
He's not qualified to lead an oncology sales force! He continues to make poor business decisions for oncology and fills any and every open position in oncology with unqualified primary care reps, DMs and RSDs!
 












Anonymous said:
He's not qualified to lead an oncology sales force! He continues to make poor business decisions for oncology and fills any and every open position in oncology with unqualified primary care reps, DMs and RSDs!
Click to expand...

You people don't get. The more you slam OB, the more oncology is going to take the brunt of this "project". Did you notice that pc is not being touched in the "project". Oncology will be decimated and then those in pc will take our slots in a year when A23 continues to tank. Revenge will be sweet. He's going to show those spoiled oncology reps that Eisai can make it without them. Last person turn out the lights.
 




Anonymous said:
You people don't get. The more you slam OB, the more oncology is going to take the brunt of this "project". Did you notice that pc is not being touched in the "project". Oncology will be decimated and then those in pc will take our slots in a year when A23 continues to tank. Revenge will be sweet. He's going to show those spoiled oncology reps that Eisai can make it without them. Last person turn out the lights.
Click to expand...

Oncology needs more PC reps. Aciphex and Aricept 23 make more money than any crap you sell in Oncology. Those "oncology" drugs you sell aren't even really oncology drugs anyway.
 




Anonymous said:
You people don't get. The more you slam OB, the more oncology is going to take the brunt of this "project". Did you notice that pc is not being touched in the "project". Oncology will be decimated and then those in pc will take our slots in a year when A23 continues to tank. Revenge will be sweet. He's going to show those spoiled oncology reps that Eisai can make it without them. Last person turn out the lights.
Click to expand...

Are you an idiot???? OB is basing his decisions on revenge??? What a great leader!! OB might not be the brightest bulb but he's not a complete idiot
 




Anonymous said:
Are you an idiot???? OB is basing his decisions on revenge??? What a great leader!! OB might not be the brightest bulb but he's not a complete idiot
Click to expand...

I don't think anyone has said he is a great leader. To rationalize that getting rid of pc reps will have a negative impact on a flawed forcast with A23 demonstrates questionable strategic abilities by a leader. Keeping all of pc is not going to make the numbers change. The die has been cast on the utilization of A23. Steve Sembler couldn't even get his mother in law to use it. Maybe that's why he was let go.
 




Anonymous said:
Oncology needs more PC reps. Aciphex and Aricept 23 make more money than any crap you sell in Oncology. Those "oncology" drugs you sell aren't even really oncology drugs anyway.
Click to expand...

LOL. So Halaven and Dacogen aren't "oncology" drugs, huh? Thanks for chiming in with your seasoned and expert insight. So tell me, in your PC expert opinion, what oncologics qualify as "oncology" drugs? Aloxi may be supportive care but it is a contracted and complex business sell done through specialty pharmacy and GPO's, something most of you don't know the first thing about. It would take most of you months to get up to speed on this end of the business, time this company should realize it doesn't have.

The thought that people like this that have absolutely no clue about what qualifies as an "oncology" drug or how the business model in oncology differs from pill pushing could be the future of Eisai Oncology is a very disturbing thought. Lets hope clearer heads prevail and those with the knowledge and relationships necessary to succeed in oncology going forward are kept.
 




OB has lost his compass and this thread shows how desperate he is and how the negative posts are scaring him. OB will be out. He is here until a new CEO is appointed. First LC will leave and OB will follow.
 




Anonymous said:
Oncology needs more PC reps. Aciphex and Aricept 23 make more money than any crap you sell in Oncology. Those "oncology" drugs you sell aren't even really oncology drugs anyway.
Click to expand...

Whoever you are....all I can say is, "A mind is a terrible thing to waste...."

Go crawl under your rock again you idiot. You couldn't sell an oncology product if you were able to give it away.
 








Anonymous said:
LOL. So Halaven and Dacogen aren't "oncology" drugs, huh? Thanks for chiming in with your seasoned and expert insight. So tell me, in your PC expert opinion, what oncologics qualify as "oncology" drugs? Aloxi may be supportive care but it is a contracted and complex business sell done through specialty pharmacy and GPO's, something most of you don't know the first thing about. It would take most of you months to get up to speed on this end of the business, time this company should realize it doesn't have.

The thought that people like this that have absolutely no clue about what qualifies as an "oncology" drug or how the business model in oncology differs from pill pushing could be the future of Eisai Oncology is a very disturbing thought. Lets hope clearer heads prevail and those with the knowledge and relationships necessary to succeed in oncology going forward are kept.
Click to expand...

First of all, Dr. House, you and the majority of your oncology counterparts did not start off in pharmaceuticals as oncology reps. You came from other areas, maybe even PC. Most of the other PC folks could do your job with some decent training and a little field experience, just like you got. The ones who couldn't make the transisition are probably not even qualified to be working in PC.

Second, ocology is going to be decimated in the coming months, but so is PC. They are just getting the "flip-flop" routine from management, The company may have initially told them that there are going to be PC layoffs in the hopes that some of them would scatter on their own and thereby reduce severance costs. The only problem is, when you announce impending layoffs, salesforce production takes a total nosedive because no one feels safe and everyone spends there days dusting off their resume and dialing up the old contacts. With 6+ weeks left until the end off the fiscal year, management has announced that PC is safe in the hopes that some of them will be foolish enough to go back to work and close out the year. HO can't have it both ways!
 




Anonymous said:
LOL. So Halaven and Dacogen aren't "oncology" drugs, huh? Thanks for chiming in with your seasoned and expert insight. So tell me, in your PC expert opinion, what oncologics qualify as "oncology" drugs? Aloxi may be supportive care but it is a contracted and complex business sell done through specialty pharmacy and GPO's, something most of you don't know the first thing about. It would take most of you months to get up to speed on this end of the business, time this company should realize it doesn't have.

The thought that people like this that have absolutely no clue about what qualifies as an "oncology" drug or how the business model in oncology differs from pill pushing could be the future of Eisai Oncology is a very disturbing thought. Lets hope clearer heads prevail and those with the knowledge and relationships necessary to succeed in oncology going forward are kept.
Click to expand...

You talk a big game yet your "oncology" drugs make no money. So keep telling me how complex your job is and we'll keep paying the bills in PC you little man.
 








Anonymous said:
You talk a big game yet your "oncology" drugs make no money. So keep telling me how complex your job is and we'll keep paying the bills in PC you little man.
Click to expand...

Seriously? How hard is it to get a signature and drop some samples you little PC shit. Obviously you PC brats are doing enough to pay the bills...the entire National Meeting was a continuous discussion about how A23 isn't making it's numbers...Talk to me when you have more experience than "Hey Doc can you sign for samples" and "thanks Doc"...You couldn't sell an Oncology product if OB had a gun to your manhood...SHUTUP
 




Anonymous said:
Oncology needs more PC reps. Aciphex and Aricept 23 make more money than any crap you sell in Oncology. Those "oncology" drugs you sell aren't even really oncology drugs anyway.
Click to expand...


Perfect example of a sorry PC rep that desperately wants in Oncology...it will happen little buddy! OB is in charge so ALL of PC reps will be the Oncology reps for Eisai very very soon!!! OB and LC....what amazing leadership!
 








Specialty Pharmacies stock drugs like remicade
Gastros prescribe drugs like remicade
I call on Gastros with a consultative selling style
I understand the coding required for reimbursement to occur
I could sell Specialty Pharma meds

Infusion Meds include drugs like Reclast. Sold by primary care reps. How about the buy and bill model?
Drugs like Prolia? Yes, Primary Care Reps sold those, too.

All that you onc reps have is a little focused education and time in the saddle. ANY Primary Care jockey can do it with a few weeks home study and a few weeks at home office.

Capitalism Rule #1: All employees are replacable.
 




ANY Primary Care jockey can do it with a few weeks home study and a few weeks at home office.[/QUOTE said:
lol....a few weeks study and a few weeks at home office, no wonder MD's don't want to see you. MD's recognize a few weeks study and a few weeks at the home office. That is exactly the flawed mentality that got Eisai and their friends at Pfizer and Sanofi into this mess.. Instead of basing decisions on well planned knowledge of the market and carefully crafted execution, we get a "dramatic leap plan" right over the cliffs. EISAI=Empoyees Income Suddenly and Abruptly Interrupted...With all that is going on in the government, wall street and industry, this country is suffering from a major shortage of leadership....
Click to expand...
 




Anonymous said:
lol....a few weeks study and a few weeks at home office, no wonder MD's don't want to see you. MD's recognize a few weeks study and a few weeks at the home office. That is exactly the flawed mentality that got Eisai and their friends at Pfizer and Sanofi into this mess.. Instead of basing decisions on well planned knowledge of the market and carefully crafted execution, we get a "dramatic leap plan" right over the cliffs. EISAI=Empoyees Income Suddenly and Abruptly Interrupted...With all that is going on in the government, wall street and industry, this country is suffering from a major shortage of leadership....
Click to expand...

It is never wise to assume that what you do cannot be done by anyone else. Controlled distribution, buy and bill, complex disease state --Oncology is not the only area that has these. But the PP is right, a reasonably intelligent specialty rep with extra disease related training will get it. After that it is experience and practice which is true for any drug PC/SP/Onc. The more you do it the better you get at it. There was a time people used to laugh at Japanese cars. Now Lexus is the symbol of luxury and fine engineering.
 




Top Bottom
Back
Quote